Evaluation of prognostic factors in patients with therapy-related acute myeloid leukemia
Sang-Hyuk PARK; Hyun-Sook CHI; Young-Uk CHO; Seongsoo JANG; Chan-Jeoung PARK.
Blood Research
; : 185-192, 2013.
Artículo en Inglés | WPRIM | ID: wpr-172219
Documentos relacionados
Recurrent Translocations in Topoisomerase Inhibitor-Related Leukemia Are Determined by the Features of DNA Breaks Rather Than by the Proximity of the Translocating Genes.
Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.
Genetic abnormalities in leukemia secondary to treatment in patients with Hodgkin's disease.
Acute myeloid leukemia following etoposide therapy for EBV-associated hemophagocytic lymphohistiocytosis: a case report and a brief review of the literature.
What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?
Antitumor Effect of <i>Glandora rosmarinifolia</i> (Boraginaceae) Essential Oil through Inhibition of the Activity of the Topo II Enzyme in Acute Myeloid Leukemia.
Etoposide promotes DNA loop trapping and barrier formation by topoisomerase II.
Chromosomal translocations involving the MLL gene: molecular mechanisms.
t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?
[Radiation-induced and therapy-related AML/MDS].